Clinical Trials Logo

Unresectable Solid Neoplasm clinical trials

View clinical trials related to Unresectable Solid Neoplasm.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03326258 Withdrawn - Metastatic Melanoma Clinical Trials

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

Start date: April 20, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This phase Ib/II trial studies the best dose of glembatumumab vedotin when giving together with nivolumab and ipilimumab in treating patients with solid tumor that has spread to other places in the body and cannot be removed by surgery. Monoclonal antibodies, such as glembatumumab vedotin, nivolumab, and ipilimumab, may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT03217253 Withdrawn - Clinical trials for Metastatic Malignant Solid Neoplasm

Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction

Start date: March 16, 2018
Phase: Phase 1
Study type: Interventional

This phase I trial studies the best dose and side effects of tazemetostat in treating patients with solid tumors or B-cell lymphomas with liver dysfunction that have spread to other places in the body or cannot be removed by surgery. Tazemetostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.